Table 2 Predictors of the initiation of different anti-Parkinson medications
From: Treatment initiation for parkinson’s disease in Australia 2013–2018: a nation-wide study
Adjusted odds ratios (ORs), 95% Confidence Intervals (CIs)a,b | ||||
|---|---|---|---|---|
Non-ergot DAs (n = 1184) | MAO-B inhibitors (n = 171) | Anticholinergics (n = 168) | Combination of ≥ 2 groups (n = 191) | |
Aged < 65 years | 3.64 (3.04–4.37) | 1.66 (1.12–2.47) | 6.44 (4.40–9.43) | 2.15 (1.48–3.13) |
Women | 1.55 (1.34–1.80) | 0.84 (0.60–1.18) | 1.14 (0.82–1.58) | 1.04 (0.76–1.41) |
Concessional beneficiary | 0.97 (0.80–1.18) | 0.65 (0.44–0.95) | 1.77 (1.16–2.70) | 0.79 (0.54–1.15) |
Use of propranolol | 0.51 (0.34–0.75) | 2.11 (1.22–3.65) | 1.79 (1.00–3.20) | 1.08 (0.58–2.01) |
Use of any analgesic | 1.64 (1.40–1.93) | 0.78 (0.56–1.09) | 1.13 (0.79–1.61) | 0.91 (0.67–1.25) |
Use of antidepressants | 1.27 (1.09–1.47) | 0.84 (0.59–1.21) | 0.84 (0.59–1.19) | 0.99 (0.72–1.36) |
Use of antipsychotics | 0.67 (0.36–1.24) | 0.49 (0.07–3.62) | 8.56 (4.72–15.52) | 0.64 (0.15–2.68) |
Use of BZDRs | 1.70 (1.45–2.01) | 0.60 (0.36–1.00) | 1.59 (1.10–2.31) | 1.40 (0.98–1.99) |
Any cardiovascular disorder | 0.77 (0.64–0.93) | 0.72 (0.50–1.05) | 0.87 (0.58–1.30) | 1.10 (0.75–1.62) |
Diabetes | 1.09 (0.90–1.32) | 0.69 (0.41–1.16) | 1.11 (0.70–1.74) | 0.75 (0.48–1.16) |
Gastric acid disorder | 1.53 (1.29–1.81) | 0.80 (0.50–1.27) | 1.05 (0.69–1.61) | 1.12 (0.77–1.64) |
Reactive airway disease | 1.26 (1.07–1.47) | 1.00 (0.70–1.42) | 1.04 (0.72–1.48) | 1.21 (0.87–1.67) |
Osteoporosis/Paget’s | 0.74 (0.58–0.94) | 0.57 (0.28–1.15) | 0.81 (0.44–1.49) | 0.61 (0.35–1.09) |